Non-alcoholic Fatty Liver Disease (NAFLD)
Metabolic·MeSH: Non-alcoholic Fatty Liver Disease
Prevalence
25000.0 / 100K
Incidence
2000.0 / 100K/yr
2 drugs in development·2 companies·3 clinical trials
Drug Pipeline by Phase
Preclinical(1)
| Drug | Company |
|---|---|
| AGTX-2003 (RTI-1092769) | Agentix Corp. (AGTX) |
Unknown(1)
| Drug | Company |
|---|---|
| legalon | Mylan II B.V. (MYL) |
Compare drugs
Frequently asked questions
How many drugs are in development for Non-alcoholic Fatty Liver Disease (NAFLD)?
BioSniper tracks 2 drugs in development for Non-alcoholic Fatty Liver Disease (NAFLD) across 2 companies.
How many clinical trials target Non-alcoholic Fatty Liver Disease (NAFLD)?
There are 3 clinical trials targeting Non-alcoholic Fatty Liver Disease (NAFLD) tracked by BioSniper.
What is the prevalence of Non-alcoholic Fatty Liver Disease (NAFLD)?
The estimated prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) is approximately 25000.0 per 100,000 population.
Deep-dive into Non-alcoholic Fatty Liver Disease (NAFLD)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis